期刊
MULTIPLE SCLEROSIS JOURNAL
卷 28, 期 12, 页码 1881-1890出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/13524585221096975
关键词
Multiple sclerosis; MTR; cortical remyelination
资金
- ELA (European Leukod-ystrophy Association [2007-0481]
- INSERMDHOS [2008]
- ECTRIMS postdoctoral research fellowship
- ARSEP foundation
- ICM
- FRM (Fondation pour la Recherche Medicale)
- IUIS (Institut Universitaire d'Ingenierie en Sante, Sorbonne Universite-UPMC)
- APHP (Assistance Publique des Hopitaux de Paris)
- Investissements d'avenir [ANR-10-IAIHU-06]
By combining MTI and PET, we can study the myelin content changes in cortical and white matter lesions in patients with multiple sclerosis. This has significant implications for clinical assessment and treatment.
Objective: To investigate the clinical relevance of individual profiles of cortical and white matter lesion myelin content changes combining magnetisation transfer imaging (MTI) and 11C-PiB-positron emission tomography (PET) in patients with multiple sclerosis (MS). Methods: MTI and [C-11]PiB-PET acquired in 19 patients with MS followed up over 2-4 months and in seven healthy controls (HCs), were employed to generate individual maps of cortical and white matter (WM) lesion myelin content changes, respectively. These maps were used to calculate individual indices of demyelination and remyelination, and to investigate their association with clinical scores. Results: Cortical remyelination ranged between 1% and 5% of the total cortical volume (17%-45% of the cortical volume demyelinated at baseline). WM lesion remyelination ranged between 8% and 22% of the lesional volume. An extensive cortical remyelination was associated with a shorter disease duration (rho = -0.63, p = 0.01) and, in combination with WM lesion remyelination, explained 68%-70% of the variance of clinical scores (p < 0.01). Conclusion: Our multimodal and multicompartment approach allows us to explore single-patient cortical and WM lesion demyelination and remyelination, and to generate clinically relevant indices of myelin repair. These indices may be used as outcome measures in clinical trials, thus increasing the chance to identify successful promyelinating treatments in patients with MS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据